BioNTech mRNA Therapy Plus Keytruda Missed Its Tumor Progression Goal in HPV-Linked Head and Neck Cancer

BioNTech’s BNT113 with Keytruda did not slow HPV16-positive head and neck cancer in a Phase 2/3 first analysis. Survival data are still pending.

Have A Referral?